NCT05421572

Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 2,000 (estimated)
• Sponsor: Beijing Tsinghua Chang Gung Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China

Detailed description

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.

Conditions

• Fatty Liver Disease

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Fibrotouch	Fibrotouch will be performed showing the stiffness and fat content of liver

Timeline

• Start date: 2022-06-10
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2022-06-16
• Last updated: 2022-06-16

Locations

1 site across 1 country: China